Original news and analysis on international IP policy
By Vinayak Bhardwaj - Not a day passes in America without news of a drug company raising prices on prescription drugs. Americans pay two to six times more for prescription drugs than those living in other developed countries, who earn the same income.
Patients around the world, in developing and developed countries, are encountering barriers to access to affordable medical products, in part due to patents and resulting high prices. This is occurring despite longstanding protections built into international trade rules to allow smaller economies to act on behalf of their people and make such medical products available regardless of patents. These protections are often referred to as flexibilities in the 1994 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The prevailing view is that knowledge, understanding and use of them remains limited among policymakers and many potential beneficiaries, even as patent-strong nations and their industries work to narrow the reach and ability to use these flexibilities. In the face of this, global civil society in recent years have increasingly begun work to change the direction of this trend, with the ultimate goal of helping people everywhere - but particularly poor populations - obtain drugs they need that exist but are out of their reach. Now, the series of Intellectual Property Watch stories on this subject sponsored by Make Medicines Affordable have been translated into five languages.
Pharmaceutical companies have created an “untenable” situation by engaging in exploitative patenting practices to extend monopolies, increasing drug prices and delaying competition from more affordable generics, according to a new NGO report analysing drug prices.
Antonio Campinos, whose term as president of the European Patent Office began on 1 July, has said he wants to focus on the effectiveness of the organisation, greater global cooperation and “staff engagement.”
Negotiations for a United Nations declaration on ending tuberculosis had drawn to a close earlier this week, with the United States seeming to succeed on a hardline position to keep mention of intellectual property rights and affordability of medicines out of the text. But nongovernmental reports say the draft has not been accepted by all members and that negotiations will have to be reopened.
The call for public comments on the Copyright Amendment Bill by South Africa’s Parliamentary Portfolio Committee on Trade and Industry attracted a wide range of interest and contributions from local and international IP stakeholders.
United Nations members in the final days of negotiating the text of the declaration for a late September high-level meeting on tuberculosis have come under pressure from the United States to omit language referring to the importance of making affordable medicines available to patients in need, according to an urgent bulletin today from a health advocacy group.
Oppositions have been filed in India against two patent applications from US pharmaceutical company Gilead for important hepatitis C medicines, according to non-governmental sources. The opposition filings assert that these applications are “evergreening” patents and therefore violate Indian patent law.
South Africa’s Portfolio Committee on Trade and Industry in Parliament has published a list of select clauses of the Copyright Amendment Bill for public comment. The deadline for comments is 18 July.
The United Nations today announced it has launched a high-level panel on digital cooperation, co-chaired by Melinda Gates (wife of Bill Gates of software titan Microsoft), and Jack Ma, head of China's e-commerce titan Alibaba Group. The 20-member panel will "identify policy, research and information gaps, and make proposals to strengthen international cooperation in the digital space," according to a release.
An open letter sent by 242 organisations and individuals to key United Nations and World Health Organization representatives on 4 July demanded that high prices limiting access to medicines and effective treatment be addressed at the upcoming UN High-Level Meeting on Non-Communicable Diseases.
The European Parliament today opposed plans to launch immediate “trilogue” negotiations with the Council and European Commission on copyright reform legislation, instead sending the controversial measure to full debate at the next plenary session of Parliament.